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ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death worldwide. It is 
often diagnosed at an advanced or metastatic stage and results of the approved systemic therapies are discouraging, 
making PDAC one of most lethal cancers in Western countries. In recent years, a better comprehension of PDAC 
unique biology has disclosed new potential targets for therapeutic interventions. Meanwhile, the development of 
conjugated agents, small molecules, antibodies, and immunoagents has opened therapeutic opportunities for drugs able 
to exert therapeutic effects on druggable targets of PDAC biology. Despite some failures, this approach is bringing 
meaningful results from bench to bedside, and more efficacious therapeutic opportunities may become available for 
PDAC treatment. In this review, we discuss the main hallmarks of PDAC biology as its microenvironment, cancer-
driving proliferative pathways, growth suppression loops, and how PDAC evades immune system surveillance, as 
well as molecular aspects of each feature. The main preclinical and clinical results of each targeted intervention are 
also presented considering its biological rationale. Ongoing clinical trials provide evidence of the effectiveness of 
this approach and promising results in the treatment of PDAC.
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I. InTroDucTIon
Pancreatic ductal adenocarcinoma (PDAC) and its 
variants, usually called pancreatic cancer, is the most 
common malignancy of the pancreas, accounting for 
~85–90% of pancreatic neoplasms.1 PDAC is the 
sixth and the eight leading cause of cancer-related 
deaths worldwide and in Europe, respectively.2,3 
Only 25% of newly diagnosed PDAC patients are 
eligible for potentially curative surgery because most 
patients are diagnosed at advanced/metastatic stages 
of disease. However, despite adjuvant treatment, the 
5-year survival rate of these patients is only ~20%.4 
Cytotoxic chemotherapy represents the standard 
of care of inoperable and metastatic PDAC. Nonethe-
less, PDAC is usually resistant to systemic therapies, 
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and the 5-year survival rate is ~7%.5 Currently, the 
approved treatment regimens for systemic disease, 
such as the combination of 5-fluorouracil/leucovorin, 
oxaliplatin, irinotecan (FOLFIRINOX regimen),6 
gemcitabine, and nanoparticle albumin-bound pacli-
taxel (nab-paclitaxel)7 or other gemcitabine-based 
combinations8 offer only a few months survival 
benefit over gemcitabine monotherapy that have 
represented the standard treatment approach since 
the late 1990s.9
In past decades, relevant advances have been 
made in understanding PDAC genetic and nongenetic 
risk factors, and more recently, in comprehending 
PDAC molecular biology.
Risk factors such as smoking, diabetes mellitus, 
nonhereditary chronic pancreatitis, and obesity have 
been associated with the development of pancreatic 
tumors. It is also estimated that 5–10% of pancreatic 
cancers have an inherited component, although in 
most of cases the genetic basis for familial aggrega-
tion has not been identified.10 No effective screening 
tool for PDAC is available to detect asymptomatic 
premalignant or early malignant tumors. In addi-
tion, no protective agent against PDAC has been 
identified. Although there is a consensus regarding 
the value of a screening test in the case of inherited 
predisposition for PDAC, there is no agreement on 
the most effective screening tool or on the optimal 
interval between examinations.11,12
As far as PDAC molecular biology is concerned, 
a pivotal study covering this issue was authored by 
Jones et al,13 who showed that PDAC is driven by 
alterations of multiple genes involved in cell cycle 
regulation, metabolism, and DNA repair. In particu-
lar, the genome-wide analysis of 24 PDAC samples 
identified an average of 63 genetic alterations, mostly 
point mutations in 12 key cellular signaling pathways 
(i.e., K-RAS, SMAD4, JNK, integrin, Wnt/Notch, 
Hedgehog, small GTPase signaling) and processes 
(i.e., control of G1/S phase transition, apoptosis, 
DNA damage control, invasion, hemophilic cell 
adhesion). Each pathway was altered in 67–100% 
of the tumors studied. 
A more recent study by Biankin et al. showed 
that driver mutations in PDAC are very scarce 
(≤6–7), suggesting that such a small number is pos-
sibly sufficient for PDAC tumorigenesis.14 Through 
whole-exome sequencing of 99 PDAC samples, 
they evidenced a high number of nonsilent muta-
tions and copy number variations (2016 and 1628, 
respectively). Apart from known mutations (e.g., in 
K-RAS, TP53, CDKN2A, and SMAD4 genes), most 
of the others have rarely been reported. 14 
Today, it is recognized that activating point muta-
tions of the K-RAS oncogene are the most common 
genomic alterations in PDAC, their frequency being 
>90%. Frequencies of mutations in most commonly 
altered tumor suppressor genes range from 60–70% of 
TP53 to 5–10% of MLL1, MLL2, KDM6A. Mutations 
in other tumor suppressor genes such as CDKN2A, 
which is involved in the G1 cell cycle arrest pathway, 
are found in >50% of PDACs. Mutations in SMAD4 
and TGF-βR1/2, which are involved in the TGF-β 
pathway, are found in ~50% of PDACs. Mutations 
in ARID1A, ARID1B and SMARCA1, which are 
involved in the nucleosome remodeling, are found 
in 10–15% of PDACs and, finally, mutations in ATM 
and BRCA2, which are involved in DNA damage 
response, are found in ~10% of PDACs.15,16
Other relevant information has been derived 
from the mutational analysis of tumors and cor-
responding metastases.17,18 Results of two relevant 
studies showed that genomic instability persists after 
cancer dissemination,17 that genetic heterogeneity 
of metastases reflects the heterogeneity within the 
primary carcinoma, and that a very long time frame 
occurs between tumor initiation and progression.18 
The need of driver mutations for the development 
of seeding metastasis, in addition to those required 
for primary tumors, has also been shown.17
 The knowledge of the signaling pathways, 
processes, and driver mutations involved in PDAC 
tumorigenesis and metastasis may be useful for the 
identification of molecular biomarkers predictive 
of treatment efficacy as well as a rational approach 
to treatment.
To date, only a few studies have analyzed cor-
relations between PDAC molecular biology and 
response to treatment according, for instance, to 
genome-wide analysis (GWAS) or gene expression 
profile (GEP) approaches. However, Collisson et 
al.,19 using primary PDAC explants and human pan-
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creatic cancer cell lines, identified gene signatures 
predictive of drug responses. Their results showed 
three distinct molecular subtypes of PDAC accord-
ing to their respective gene expression patterns: 
classic, quasimesenchymal, and exocrine  like. The 
classic subtype expressed high levels of adhesion 
associated and epithelial genes (e.g., AGR2 and 
S100PBP), the quasimesenchymal subtype expressed 
high levels of mesenchyme associated genes (e.g., 
TWIST1 and S100A2), and the exocrine -like subtype 
had high expression of genes involved in digestion 
(e.g., REG3A (PAP) and PRSS1). Subtypes differed 
in response to chemotherapy (i.e., gemcitabine and 
erlotinib) in human PDAC cell lines of a known 
subtype. The quasimesenchymal subtype lines were, 
on average, more sensitive to gemcitabine than the 
classical subtype, whereas erlotinib was more effec-
tive in the classical subtype cell lines. Because the 
classical PDAC lines were relatively more dependent 
on K-RAS than quasimesenchymal subtype lines, 
the authors suggested that K-RAS mutation status 
is an imperfect predictor of sensitivity to EGFR-
targeted therapy in PDAC and implies that cancer 
cells dependent on mutant K-RAS still employ EGFR 
to some extent. 
Overall, these findings suggest that the PDAC 
subtype specificity could be exploited to select anti-
cancer drugs to maximize their efficacy. This goal 
has become mandatory considering that, despite 
improved understanding of the biology of PDAC, 
5-year survival rates are dismal, as previously dis-
cussed.5 Actually, cytotoxic drugs are not able to 
adequately target and exploit PDAC’s unique biology.
Today, only some of the above discussed altered 
events can be considered “druggable” due to multiple 
reasons (e.g., difficulties in recognizing driver from 
passenger mutations, difficulties in restoring tumor 
suppressor function, and difficulties in identifying 
targetable sites in macromolecular complexes due 
to protein-protein interactions).20 However, several 
hallmarks have been proposed for various types of 
cancer, including PDAC. These comprise biological 
capabilities acquired during multistep development 
of tumors such as tumor microenvironment, sustain-
ing proliferative signaling, inducing angiogenesis, 
evading growth suppression, and avoiding immune 
destruction.21 Some of these hallmarks depend on 
tumor-specific genetic defects that may render cancer 
cells vulnerable to synthetic lethality approaches that 
can finally kill tumor cells while sparing normal 
cells.22 In this review, we discuss targets involved 
in PDAC hallmarks and pathways. Some of these 
have already been successfully targeted in other 
neoplasms. We also focus on drugs currently under 
investigation in the most advanced phases of clinical 
trials in PDAC patients. 
II. Tumor mIcroenvIromenT
In recent years, tumors have been increasingly recog-
nized as having a heterogeneous microenvironment 
of cellular elements that include specialized types of 
cells, neoplastic cells, and extracellular matrix (i.e., 
tumor microenvironment).21 Cancer itself constructs 
a tumor microenvironment during the course of 
multistep tumorigenesis to enable tumor growth and 
spread of disease. This complex structure is composed 
by different elements that cross talk and dynamically 
erect and remodel the extracellular matrix. Cancer 
stem cells represent the foundation of the disease; 
they initiate tumors and drive its progression carrying 
genetic mutations that promote cancer itself. Cancer 
stem cells are functionally defined by their ability to 
seed new tumors upon inoculation. Endothelial cells 
form the tumor-associated vasculature fundamental 
to the nutritional and oxygen support of neoplastic 
elements. Pericytes are a specialized mesenchymal 
cells that surround the endothelium, providing it 
with a paracrine and mechanical support. Fibroblasts 
and myofibroblasts create a structural foundation 
supporting the epithelial tissue and, therefore, the 
neoplastic epithelial elements. Immune inflammatory 
cells belong to the immune system and operate with 
tumor-antagonizing and tumor-promoting functions.23 
The tumor microenvironment plays a major role 
in PDAC biology; thus, it represents a target of inter-
est for preclinical and clinical research in PDAC, 
and it has been shown to affect both tumor growth 
and therapeutic response.24,25 PDAC is characterized 
by a highly dense stroma consisting of extracel-
lular matrix components, inflammatory cells, and 
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proliferating myofibroblasts also called pancreatic 
stellate cells (PSCs). The latter are responsible for 
the production of thick extracellular matrix (ECM) 
of type I collagen, proteoglycans, and glycosami-
noglycans as hyaluronan acid.26 PSCs also deliver 
growth factors that mainly contribute to proliferation 
and survival of neoplastic elements.27,28 In addition, 
the pancreatic tumor stroma contributes to leaky 
intratumoral vasculature, reduced blood flow (there-
fore an hypoxic state), and high interstitial pressure 
that may impair drug delivery.29,30 In PDAC, tumor 
stroma are characterized by an excessive prolifera-
tion of fibrotic tissue called desmoplastic reaction 
that provides a protumorigenic environment for 
PDAC cells and contributes to the selection of more 
aggressive clones.31 The main tumor stroma targets 
that have been investigated in PDAC are secreted 
protein acidic and rich in cysteine (SPARC), the 
hedgehog (Hh) pathway, and hyaluronan acid (HA).
A.  Secreted Protein Acidic and rich in 
cysteine 
Osteonectin, also known as SPARC, is an ECM 
glycoprotein that has been shown to play a crucial 
role in tissue homeostasis.32 By binding to multiple 
structural components as collagen, interstitial proteins 
as albumin, and controlling matrix metalloproteinase 
(MMP) activity, SPARC regulates the ECM organi-
zation and turnover.33 Moreover, SPARC has a role 
in angiogenesis through direct binding of vascular 
endothelial growth factor (VEGF), thus preventing 
interactions with its receptor or through inhibitory 
effects on endothelial cells, and through regulatory 
effects on matrix cells in the production of proan-
giogenic factors.34 Finally, SPARC and transforming 
growth factor β (TGF β), as well as other growth 
factors, have complex mutual regulatory effects that 
result in matrix production and cellular growth (see 
section III.C.).35 
A role of SPARC in PDAC was theorized fol-
lowing molecular profiling studies of PDAC and 
immunostaining analysis of primary tumors in which 
SPARC was overexpressed compared with normal 
tissue.36 Moreover, the most frequent pattern is a 
cancer-cell–negative/stromal-fibroblast–positive 
SPARC expression and has been associated with a 
significantly shorter median overall survival (OS) (15 
months versus 30 months, p>0.001), irrespective of 
tumor size, grade, margin status, lymph nodes, and 
patient age.37 Although SPARC expression is a marker 
of poor prognosis because it has a high affinity for 
albumin, it has been suggested that elevated SPARC 
expression may enable albumin-bound drugs (i.e., 
nab-paclitaxel) to be retained in SPARC-positive 
areas.38 This was the biological rationale for the 
intratumoral delivery of nab-paclitaxel in PDAC.
In a phase 1–2 trial, nab-paclitaxel was used in 
combination with gemcitabine. The median OS of 
patients with high SPARC was 17.8 months versus 
8.1 months of those with low SPARC expression 
(p=.043).39 Given these positive results, nab-pacli-
taxel has been evaluated in a phase 3 trial.7 The 
primary endpoint was reached showing the superi-
ority of the combination on gemcitabine alone with 
a median OS of 8.5 versus 6.7 months (HR=0.72, 
p<0.001), respectively, leading to the approval of 
nab-paclitaxel in PDAC. A subsequent analysis of 
this phase 3 clinical trial showed that the activity of 
nab-paclitaxel was not related to SPARC expression.40 
SPARC levels were neither prognostic for survival 
nor predictive of response, making it premature 
for any treatment decisions depending on SPARC 
expression in PDAC.
B.  HeDgeHog SIgnAlIng PATHwAy 
The Hh pathway consists of three secreted ligands 
(sonic hedgehog (SHH), Indian hedgehog (IHH) 
and desert hedgehog (DHH), a negative regulatory 
receptor, patched (PTCH), the positive regulatory 
protein smoothened (SMO) and the glioma-associated 
oncogene (GLI) transcription factors (GLI1, GLI2, 
and GLI3).41 
Although Hh is silenced in normal tissue after 
embryogenesis,42 in various cancers such as PDAC it 
is aberrantly reactivated.43 Hedgehog (Hh) signaling 
occurs following the binding of Hh ligands to the 
PTCH receptor. This interaction leads to the inhibi-
tion of the PTCH receptor and, consequently, to the 
release of the G-protein-coupled receptor SMO. This 
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results in a cascade of events and in the translocation 
of the Gli transcription factor to the nucleus. The lat-
ter induces the expression of various context-specific 
genes, such as those encoding the D-type cyclins, 
c-MYC, BCL2, and SNAIL, which regulate cellular 
differentiation, proliferation, and survival and are 
typically dysregulated in cancer cells.44
Two distinct ligand-dependent activation path-
ways are supposed to underlie Hh activation: an 
autocrine pathway and a paracrine pathway. In the 
autocrine pathway, Shh transcription is directly 
increased and proliferation of pancreatic cancer cells 
is accelerated via its overexpression.1 In the para-
crine pathway, tumor-associated stroma cells secrete 
tumor-growth factors through stromal Hh signaling 
activation or, alternatively, they produce Shh, which 
stimulates in turn the Hh signaling both in PDAC 
cells and stromal cells.45,46 Thus, the Hh pathway 
plays a relevant role in determining the characteristic 
desmoplastic reaction of pancreatic neoplasms.47 
Alternatively, pancreatic cancer cells that exhibit 
stem cell characteristics (e.g., self-renewal, ability 
to produce differentiated progeny, and resistance 
towards conventional chemo- and radiotherapy) 
exhibit an upregulation of Hh.48 
Therefore, Hh inhibition can successfully target 
tumor growth, invasiveness, and the microenviro-
ment. In preclinical models, Hh inhibitors increase 
chemotherapy delivery by depleting peritumoral 
stroma and increasing vascularity; thus, their 
combination with chemotherapy agents may be an 
attractive therapeutic strategy for PDAC. In recent 
years, the Hh pathway drug discovery efforts have 
been mainly focused on targeting SMO. Currently, 
investigated inhibitors of SMO include saridegib, 
vismodegib, and sonidegib. Saridegib abrogated the 
desmoplastic reaction, leading to increased delivery 
of chemotherapy in a murine model of pancreatic 
cancer.49 However, despite these encouraging results, 
the combination of saridegib and gemcitabine failed 
to reach the planned endpoint of a phase 2 clinical 
trial (NCT01130142).50 The combination of saridegib 
with a more intensive chemotherapy regimen (i.e., 
FOLFIRINOX) has also been explored. Preliminary 
results of this ongoing study showed that this com-
bination has encouraging activity and manageable 
toxicity.51 Vismodegib, another Hh inhibitor, failed 
to show antitumor activity in a phase 1b clinical 
trial in combination with gemcitabine,52 whereas 
the combination of vismodegib, gemcitabine, and 
nab-paclitaxel showed preliminary evidence of activ-
ity in an ongoing phase 2 trial.53 Finally, phase 1/2 
clinical trials of sonidegib (LDE225) in combination 
with gemcitabine and nabpaclitaxel (NCT01431794; 
NCT02358161)54,55 or phase 1 trials of sonidegib 
with gemcitabine alone (NCT01487785)56 or FOL-
FIRINOX57 are ongoing, and their results are eagerly 
awaited. Thus, targeting desmoplasia remains an 
attractive approach because it may affect drug deliv-
ery and inhibit PDAC progression.
c.  Hyaluronan Acid
In physiological conditions, the amount of HA 
in extracellular matrix is controlled by a balance 
between its synthesis and degradation.58 HA is 
abundantly produced in the surrounding stroma of 
malignant tumors, where it plays a role in tumor pro-
gression by enhancing cell proliferation, migration, 
invasion, metastasis, angiogenesis, and resistance to 
chemotherapeutic agents. In fact, HA overexpres-
sion may contribute to poor outcomes by reducing 
delivery of anticancer agents from the bloodstream.59 
In preclinical models, the elimination of HA normal-
izes interstitial fluid pressure and increases vascular 
perfusion, thereby permitting drug delivery into 
neoplastic tissue.60 Human-recombinant PEGylated 
hyaluronidase (PEGPH20) represents an interesting 
approach to targeting pancreatic stroma by depleting 
HA that is abundant in the ECM of PDAC.61 In a 
phase 1b study, patients with stage IV previously 
untreated PDAC were treated with PEGPH20 in 
combination with gemcitabine. A high response rate 
was reported in patients with elevated HA tumor 
staining, without major drug-related side effects.62 
PEGPH20 is currently being investigated in other 
clinical trials in PDAC. In particular, the addition of 
PEGPH20 to standard chemotherapy regimens (e.g., 
the combination of gemcitabine and nab-paclitaxel 
or the FOLFIRINOX regimen) is under investigation 
(NCT01839487; NCT01959139).63,64
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D.  other Stroma Targets
Other stroma-targeting compounds currently under 
evaluation include the combination of the heparin 
derivative ODSH (2-O,3-O desulfated heparin), a 
low-molecular-weight heparin that inhibits extracel-
lular proteoglycans and growth factor receptors.65 
Cationic liposomal paclitaxel (EndoTag-1) is pacli-
taxel embedded in cationic liposomes that enhance the 
compound affinity to negatively charged damaged 
tumor vessels. Results of a phase 2 trial66 comparing 
cationic liposomal paclitaxel plus gemcitabine versus 
gemcitabine alone were promising; however, these 
results should be confirmed in a phase 3 trial.
Finally, taking advantage of the hypoxic state 
of the tumor microenvironment, the use of prodrugs 
that must be activated under hypoxic environment to 
obtain better drug delivery could result in a tumor-
targeted treatment strategy. TH302, a prodrug of 
dibromo-isophosphamide mustard, an alkylating 
agent, is activated in hypoxic conditions. It has 
been evaluated in a randomized phase II trial with 
positive results in association with gemcitabine in 
PDAC patients.67 Interestingly, the combination treat-
ment did not determine major toxicities compared 
to gemcitabine monotherapy.
III. SuSTAInIng ProlIferATIve SIgnAlIng
Uncontrolled cell proliferation is recognized as one 
of the most fundamental traits of cancer cells and 
directly involves their capability to undergo uncon-
trolled growth irrespectively of tissue architecture 
and cell number homeostasis.68 In healthy tissues, 
proliferative signals are mainly provided by growth 
factors that bind cell-surface receptors, usually 
containing a catalytic tyrosine kinase domain that 
activates intracellular pathways to regulate cell cycle 
growth and apoptosis.69 Cancer cells may acquire 
their proliferative capability in different modalities: 
they may produce growth factor ligands themselves 
or they may stimulate tumor-associated stroma to 
produce growth factors useful for their proliferation 
and survival. Alternatively, cancer cells may undergo 
enhanced growth and proliferation overexpressing 
or producing abnormal growth factor receptors that 
generate a ligand independent signaling. Similarly, 
constitutively activated downstream mediators may 
confer growth autonomy to cancer cells.69
As for other neoplasms, abnormal cell prolifera-
tion is a common feature of pancreatic cancer cells. 
In PDAC, this event mainly involves the epidermal 
growth factor receptor (EGFR)-RAS/RAF/MEK/
ERK pathway that is abnormally activated in >90% 
of preinvasive pancreatic lesions.70 On the binding of 
key ligands (e.g., EGF or TGF-b), EGFR homo- or 
hetero-dimerizes with other members of the same 
receptor family, resulting in autophosphorylation of 
the intracellular receptor domain and recruitment 
of signaling complexes that activate a variety of 
downstream pathways, including PI3K/AKT/mTOR, 
STAT, and RAS-ERK, leading to uncontrolled cell 
proliferation.71 Other factors and membrane recep-
tors under investigation as druggable targets include 
insulin-like growth factor (IGF), transforming 
growth factor b (TGF-b), and hepatocyte growth 
factor receptor (HGFR). Currently, direct inhibition 
of these factors and receptors and their pathways 
is undergoing preclinical and clinical evaluations 
in PDAC. 
A.  epidermal growth factor receptor 
As mentioned, EGFR is overexpressed in PDAC, 
and EGFR signaling is essential for K-RAS mutant 
PDAC.72 Moreover, EGFR expression has been 
related to tumor aggressiveness, suggesting EGFR 
as a key promoter of PDAC development and a 
potential target for its treatment.73 Targeting EGFR 
in PDAC therapy has been investigated using differ-
ent approaches: (1) tyrosine kinase inhibitors of the 
EGFR intracellular domain that block its activation 
and downstream signaling pathway recruitment or 
(2) monoclonal antibodies (MoAbs) that, binding 
the EGFR extracellular domain, prevent receptor 
dimerization and activation.
Erlotinib, a tyrosine kinase inhibitor (TKI) of 
HER-1/EGFR, has been intensively studied in PDAC. 
In a phase 3 trial, the combination of gemcitabine 
and erlotinib showed a minimal but statistically sig-
nificant survival advantage compared with standard 
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gemcitabine monotherapy (median OS 6.24 and 
5.91 months in the experimental and in the control 
groups, respectively, p=.004).74 On this basis, erlo-
tinib was approved in metastatic PDAC, although 
its clinical utility is dismal due to the small survival 
benefit. Currently, given the relative success of adding 
nab-paclitaxel to gemcitabine and that of the FOL-
FIRINOX regimen, the role of erlotinib in PDAC is 
considered to have scanty relevance and no longer 
constitutes a standard of treatment for this disease.6,7 
Cetuximab, a MoAb directed against the extra-
cellular domain of EGFR, has been evaluated in 
metastatic PDAC.75 Despite promising initial results, 
the association of cetuximab to gemcitabine failed 
to obtain statistically significant results in a phase 
3 clinical trial.76 Several explanations have been 
suggested; however, the constitutive activation of 
downstream elements such as K-RAS is reported 
as the most likely.
Other EGFR-targeted MoAbs under investigation 
in PDAC are nimotuzumab, matuzumab and pani-
tumumab. Promising results have been reported in 
phase 2 studies. One of these included nimotuzumab 
in association with gemcitabine versus gemcitabine 
alone;77 another involved the dual blockade of EGFR 
by panitumumab and erlotinib in association with 
gemcitabine versus erlotinib and gemcitabine.78 Phase 
3 trial results are awaited. 
Strategies to enhance the antibody targeting of 
EGFR and consequently the clinical efficacy are cur-
rently being explored in preclinical pancreatic cancer 
models and include the possibility to combine two 
MoAbs recognizing distinct epitopes able to target 
the same ErbB protein.79
B.  Insulin-like growth factor 1 
The insulin-like growth factor 1 (IGF-1) pathway 
is also expressed in the majority of PDACs and is 
involved in the activation of PI3-kinase/AKT/mTOR 
and MEK/ERK pathways.80 Cixutumumab, a MoAb 
against IGF-1, has been tested in a phase 2 clinical 
trial in combination with gemcitabine and erlotinib 
versus gemcitabine and erlotinib without evidence of 
efficacy advantages but with increased toxicity.81 In 
addition, the development of another IGF-1 MoAb, 
ganitumumab, has been stopped in PDAC due to 
negative results from a phase 3 trial.82
c.  Transforming growth factor-b 
Transforming growth factor-β (TGF-β) is involved 
in epithelial-to-mesenchymal transition (EMT), inva-
sion, and stroma-tumor dialogue and represents a 
potential therapeutic target in many tumors.83 TGF-β 
is a commonly expressed signaling mediator in PDAC 
and represents one of the most commonly genetically 
altered pathways in this cancer, displaying a central 
role in the development of desmoplastic reaction.13 
The inhibition of this pathway may be obtained 
through different approaches, such as (1) the inhibi-
tion of TGF-β receptors, (2) ligand binding to the 
TGF-β receptor by MoAbs, or (3) the inhibition of 
downstream signaling pathways by protein kinase 
inhibitors. The antisense oligonucleotide trabedersen 
(AP 12009) that specifically inhibits TGF-β2 expres-
sion achieved promising results in a phase 1/2 trial 
that included PDAC patients.84
D.  meT Proto-oncogene Tyrosine Kinase 
receptor 
MET, also called HGFR, is a membrane receptor 
with intrinsic tyrosine kinase activity that is essential 
for embryonic development and wound healing. It is 
abnormally expressed in PDAC and has an essential 
role in cell survival, growth, and the angiogenic 
switch.85 The MET inhibitor cabozantinib is cur-
rently under investigation in an ongoing phase 1 
trial in PDAC patients (NCT01663272).86 Another 
MET inhibitor, tivantinib, that is currently undergo-
ing intensive clinical investigation in several solid 
tumors showed promising results in in vitro PDAC 
models.87
Iv.  InDucIng AngIogeneSIS
Tumor invasion and progression requires sustenance 
of tumor cells with nutrients. The development of 
tumor-associated neovasculature provides tumor 
cells with nutrients and oxygen while it evacuates 
metabolic wastes and carbon dioxide. This leads to 
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tumor growth and metastasis. Angiogenic switch is a 
major determinant of tumor development and causes 
normal vasculature to sprout new vessels that help 
neoplastic growth.88 Vascular endothelial growth 
factor (VEGF) and its receptors are promoters of 
tumor angiogenesis. 
A.  vascular endothelial growth factor 
and vascular endothelial growth 
factor receptor 
Despite a promising pharmacological rationale, the 
combination of gemcitabine plus the anti-VEGF 
MoAb bevacizumab failed to improve progression-
free survival (PFS) and OS in PDAC patients.89 
Similarly, aflibercept, a MoAb that traps VEGF-
A/B and placental growth factor, which is currently 
approved in metastatic colorectal cancer, did not 
improve OS when combined with gemcitabine in 
PDAC patients.90 
 The VEGF receptor (VEGFR) has been targeted 
with other drugs that block its activity. Axitinib, a TKI 
inhibitor of VEGFR1-3 and other receptors (PDGFRβ 
and c-Kit) that affects mainly tumor angiogenesis, 
showed no benefit when combined with gemcitabine 
compared to gemcitabine alone in a phase 3 trial.91 
Similarly, sorafenib, a multikinase inhibitor of 
VEGFR1-3, PDGFRβ, Kit, RET, and Raf-1, after 
promising results in xenograft models92 and in a 
phase I trial,93 failed to show a significant benefit 
when added to gemcitabine94 or to gemcitabine and 
cisplatin in phase 2 trials.95 
In phase 2 trials, sunitinib, a multikinase inhibitor 
targeting VEGFR, did not show activity in advanced 
PDAC in monotherapy or in combination with gem-
citabine.96,97 However, sunitinib showed interesting 
results in PFS and disease stabilization when it was 
added as maintenance therapy after 6-months of stan-
dard gemcitabine chemotherapy.98 Thus, the role of 
the antiangiogenic therapy in PDAC remains unclear. 
v.  evADIng growTH SuPPreSSorS
Cell homeostasis is ensured by a multitude of nega-
tive feedback loops that normally cooperate to silence 
positive signals. Defects in these negative feedback 
mechanisms may enhance proliferative signals or 
may act as a positive signal themselves for cellular 
growth. Moreover, such mechanisms may also inhibit 
apoptosis.21 
Among control loops of cellular homeostasis, 
the Kristen rat sarcoma (K-RAS) oncoprotein rep-
resents a key checkpoint stimulating downstream 
signaling pathways that drive many of the hallmarks 
of cancer  such as sustained proliferation, metabolic 
reprogramming, anti-apoptosis, remodeling of the 
tumor microenvironment, evasion of the immune 
response, cell migration, and metastasis. 
K-RAS is expressed as two isoforms (i.e., 
K-RAS4A, K-RAS4B) that, together with H-RAS 
and N-RAS isoforms, belong to the RAS monomeric 
small G protein family. K-RAS4B is the dominant 
isoform and is thought to be the major effector of 
the oncogenic activity ascribed to mutant K-RAS.99 
In normal cells, RAS cycles between GTP-bound 
active and GDP-bound inactive states, by guanine 
nucleotide exchange factors (GEFs), which aid in 
the exchange of GDP for GTP. RAS activates the 
RAF/MEK/ERK signaling cascade, and RAS inac-
tivation is mediated by GTP-ase-activating proteins 
(GAPs), which induce the hydrolysis of GTP.100 RAS 
oncogenic activating mutations are responsible for 
maintaining the protein in the GTP-bound form, 
thus, in a constitutively active form, independently 
from the stimulation of growth factors. 
An analogous control loop involves a tensin 
homolog deleted on chromosome 10 phosphatase 
(PTEN). Its primary target is the phosphatidyl-inositol 
3,4,5 triphosphate (PIP3), produced by phosphati-
dylinositol 3-kinase (PI3K).101 Loss of PTEN results 
in an accumulation of PIP3 that mimics the effect 
of PI3K activation and triggers the activation of its 
downstream effectors as AKT. The activation of the 
latter stimulates cell cycle progression, survival, 
metabolism, and migration through many subsequent 
pathways.101 AKT activity is therefore regulated by 
PI3K, which recruits AKT to the cell membrane, 
permitting its activation. AKT is also phosphorylated 
and activated by growth factors, including IGF1, 
increasing the complexity of this control loop. AKT 
also plays an important role in promoting cell sur-
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vival.102 Targeting these checkpoints is an intriguing 
challenge in the treatment of cancer, including PDAC. 
A.  rAS-rAf-meK-erK Pathway
Mutationally activated K-RAS results in active sig-
naling of intracellular mitogenic pathways, includ-
ing RAF-MEK-ERK, PI3K/Pdk1/AKT, and the Ral 
guanine nucleotide exchange factor pathway, even in 
absence of proper stimulatory signals.103 Activating 
mutations of K-RAS found in human PDAC occur 
mainly as point mutations at codon G12 (98%) and, 
to a far lesser extent, at codons G13 and Q61. They 
impair intrinsic GTPase activity of the K-RAS pro-
tein and can block the interaction between K-RAS 
and GAPs. This leads to constitutive activation of 
K-RAS and persistent stimulation of downstream 
signaling pathways.104,105
Targeting K-RAS and other molecules such 
as MEK-1 and -2 is an ongoing challenge in 
PDAC research; it is under evaluation by different 
approaches.106,107 Farnesyltransferase inhibitors, 
such as tipifarnib, block the prenylation step that is 
required for membrane localization of RAS proteins, 
providing a therapeutical option as supported by 
preclinical results.108 Unfortunately, tipifarnib was 
unsuccessful in a phase 3 PDAC clinical trial com-
paring its association with gemcitabine versus gem-
citabine alone.109 Several reasons could explain these 
disappointing results. Some RAS family members 
may utilize other steps, such as geranylgeranylation 
for membrane localization. On this basis, a strategy 
involving the dual blockade of farnesyltransferase 
and geranylgeranyltransferase was suggested. Despite 
the strong rationale, this approach failed in clinical 
trials due to toxicity.8 Furthermore, it is unknown 
whether membrane binding is necessary for mutated 
RAS activity.
However, due to the relevance of K-RAS in 
pancreatic malignancies, other compounds are under 
investigation. The RAS inhibitor, salirasib (i.e., 
s-trans transfarnesylthiosalicylic acid, FTS) by com-
peting with farnesylated RAS for binding to escort 
proteins called galectins, may block RAS localization 
to plasma membrane, resulting in a downregulation of 
this pathway.110 However, salirasib failed in a phase 
2 clinical trial concerning K-RAS-mutated stage IIIB/
IV lung adenocarcinoma,111 and despite some activ-
ity in a phase 1 study in PDAC patients, no other 
clinical trial with salirasib is currently ongoing due 
to the discontinuation of its development.112 
A novel compound named phospho-FTS (PFTS 
or DC-1016) showed increased inhibition of K-RAS 
and increased tumor suppression when compared 
with salirasib, and it effectively prevented PanIN 
formation in a transgenic mouse model.113 K-RAS 
has also been targeted with a novel small interfering 
RNA (siRNA) delivery system termed ‘local drug 
eluter’ (LODER). In preclinical PDAC models, this 
approach showed promising activity.114 The results 
of a phase 1 trial of local delivery of G12D siRNA 
in the tumor region through endoscopic ultrasound, 
followed by chemotherapy administration with two 
different schedules (gemcitabine monotherapy or 
FOLFIRINOX regimen), showed no dose-limiting 
toxicities and disease stability in 100% of patients 
on imaging with a reduction of CA-19-9 in 64% of 
cases.115 Results of a phase 2 trial with LODER in 
patients with unresectable, locally advanced, PDAC 
are awaited (NCT01676259).116
MEK inhibitors pimasertib (MSC1936369B) and 
refametinib (BAY-869766) are under investigation 
in many cancers including PDAC, but the avail-
able results of two phase 2 trials are controversial: 
pimasertib failed to meet the primary endpoint of 
PFS advantage in combination with gemcitabine 
monotherapy,117 whereas refametinib showed prom-
ising activity in the same setting.118 Interestingly, 
biomarker results of the study combining refametinib 
and gemcitabine were also reported.119 Sixty-five 
percent of the enrolled patients had K-RAS muta-
tions (mainly K-RAS G12D, G12V, and G12R). The 
most frequent co-occurring somatic mutations or 
amplifications were TP53, CDKN2A, and cMYC. A 
trend toward improved response, median PFS, and 
OS in the wild-type K-RAS subset was observed. 
Another MEK inhibitor, selumetinib, was investi-
gated in gemcitabine refractory pancreatic cancers 
with no success.120
Resistance to MEK inhibitors may be a conse-
quence of different escape mechanisms. For example, 
the pharmacological inhibition of MEK leads to 
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enhanced signaling through EGFR independent of 
K-RAS mutational status. To overcome this negative 
feedback loop, a therapeutic strategy of combined 
target inhibition of EGFR and MEK has been 
investigated in a phase 2 trial with erlotinib and 
selumetinib, with promising results.121 Moreover, 
K-RAS can activate a variety of pathways other 
than the RAS-RAF-MEK-ERK pathway, such as 
PI3K/AKT, making useless the inhibition of a single 
component (see section V.B.). 
An interesting strategy, currently only being inves-
tigated in vitro, is represented by the combination of 
the multitarget inhibitor sorafenib (see section IV.A.) 
and vitamin K1 in pancreatic cell lines. Results showed 
elevated levels of activated c-Jun N-terminal kinase 
(JNK) and its substrates c-Jun and FasL, leading to cell 
growth inhibition and apoptosis. This effect involved 
both inhibition of the RAF/MEK/ERK pathway as well 
as activation of the JNK, c-Jun, and FasL apoptotic 
pathways.122
B.  PI3K/AKT/mTor Pathway
The PI3K/AKT/mTOR pathway plays an important 
role in cancer cells regulating survival, proliferation, 
differentiation, and metabolism.123 As mentioned, 
dual PI3K and MEK inhibition may result in a better 
blockade of RAS signaling downstream pathways. 
Combining MEK inhibitors with antagonists of PI3K/
AKT/mTOR pathway may also represent a promising 
strategy to overcome the occurrence of resistance. In 
vitro and in vivo studies support this hypothesis.124 
In subcutaneous xenograft mouse models, the PI3K 
inhibitor pictilisib (GDC0941) exhibited low anti-
tumor activity as monotherapy but enhanced the 
efficacy of the MEK inhibitor selumetinib when used 
in combination.124 Clinical trials with MEK inhibi-
tors and antagonists of PI3K/AKT are ongoing in 
various cancers, including PDAC (NCT01337765, 
NCT01363232, NCT01155453).125–127 Unfortunately, 
despite effectiveness in pancreatic neuroendocrine 
neoplasms, the mTOR inhibitor everolimus128,129 
failed in PDAC when administered to chemotherapy 
refractory patients.
The inhibition of PI3K/PKB/mTOR, Stat3, and 
FKHR pathways, as well as inhibition of tumor 
growth has been shown in a human orthotopic 
primary pancreatic cancer xenograft using the inte-
grin-linked kinase (ILK) QLT0254. An increase of 
gemcitabine-induced apoptosis has been also shown 
by adding such an inhibitor.130
vI.  genome InSTABIlITy
Acquisition of multiple hallmarks of cancer mainly 
depends on the addition of genomic alterations in 
neoplastic cells. This confers a selective advantage 
to subclones of neoplastic cells and enables their 
outgrowth and dominance in the neoplastic envi-
ronment, creating the basis for tumor progression. 
Therefore, a succession of chance acquisition of 
an enabling mutant genotype may promote clonal 
expansion of neoplastic cells.21 Some clonal expan-
sion may be acquired by epigenetic mechanisms 
(e.g., DNA methylation and histone modifications) 
triggered by nonmutational changes. Some others 
are achieved through a direct breakdown of genome 
integrity. Surveillance systems normally monitor 
genome integrity and force genetically damaged 
cells into senescence or apoptosis. However, if 
such systems are damaged, integrity of genome is 
impaired, giving advantage for tumor progression.21 
The most important mechanism for repair of DNA 
double-strand breaks is homologous recombination. 
Severe chromosomal aberrations that commonly 
lead to cell death are due to the blockage of this 
event. BRCA1 and -2 genes are frequently mutated 
in many cancers including PDAC. Because BRCA 
is a crucial component of intracellular homologous 
recombination, double-strand break repair is defective 
in affected cells. In contrast, both single strand and 
base excision repair are controlled by mechanisms 
independent of BRCA. Single-strand break repair 
definitively depends on poly-ADP-ribose polymerase 
(PARP), whereas the role of PARP in base excision 
repair is not fully understood.131,132 
BRCA1/2 harbors particular therapeutic interest 
because homozygous mutant pancreatic cells are 
particularly sensitive to DNA cross-linking agents 
such as mitomycin C and cisplatin as well as PARP 
inhibitors.133
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Because PARP inhibitors trigger cell death in 
BRCA deficient cells, they have received atten-
tion in cancer therapy. In PDAC, some clinical 
trials are assessing the role of PARP inhibitors 
such as veliparib, rucaparib, alvocidib, and BMN 
673. Veliparib in combination with a gemcitabine/
cisplatin (NCT01585805)134 or FOLFOX regi-
men (NCT01489865)135 is undergoing phase 2 
studies. Other PARP inhibitors are under earlier 
clinical evaluation (NCT01286987, NCT02042378, 
NCT00047307).136–138 
vII. evADIng THe Immune SySTem
Immune surveillance constantly monitors cells and 
tissue and is responsible for recognizing and eliminat-
ing cancer cells at an early stage. Thus, when tumors 
are detectable they have already avoided the immune 
system that resulted in an inability to eradicate tumor 
cells or to limit their extent. Many theories have been 
suggested to explain this phenomenon.21,139 The inci-
dence of some tumors (e.g., virus-associated cancer) 
is increased in immunocompromised individuals. 
Cancer cells may present a different immunogenic 
phenotype, which in turn may result in good or weak 
“immunoediting.”140 It has been suggested that dur-
ing cancer growth, highly immunogenic clones are 
recognized and disrupted by immune cells, inducing 
a positive selection for weakly immunogenic clones, 
which in turn may grow up and proliferate and elud-
ing the immune systems controls. More recently, 
immunosuppressive factors have been indicated as 
the main mechanism for immune evasion. Cancer 
cells may paralyze infiltrating cytotoxic cells by 
producing immunosuppressive factors. Moreover, the 
production of active immunosuppressive factors by 
inflammatory cells themselves and the recruitment 
of immunosuppressive immune cells may represent 
a fundamental mechanism by which tumors evade 
immune response or the immune system does not 
recognize cancer cells.21 Immunotherapy has been 
considered an ineffective strategy in cancer therapy 
for a long time. In recent years, a better under-
standing of the immune system checkpoints and 
blockade mechanisms, as well as the development 
of new immunomodulatory agents and MoAbs able 
to interfere with immune response, has opened a 
new scenario for immunotherapy in many tumors, 
including PDAC.141 
Many approaches are currently being investigated 
in clinical trials; they differ according to the mecha-
nism used to interact with the immune response. 
A. Immune checkpoints 
Immune checkpoints are inhibitory pathways by 
which the immune system maintains self-tolerance 
and prevents the development of autoimmunity.142 
Tumors exploit some immune checkpoint pathways, 
thus subverting antitumor immunity (mainly T-cell 
responses). Because most immune checkpoint 
pathways are initiated by ligand-receptor interac-
tions, they can be blocked by MoAbs and inhibitory 
peptides or modulated using recombinant forms 
of ligands or receptors.143 This may drive effector 
immune responses and enhance the efficacy of tumor 
vaccines and immunotherapeutics.
Ipilimumab is a MoAb that targets cytotoxic 
T-lymphocyte antigen 4 (CTLA-4). Because CTLA-4 
is normally expressed on the surface of T cells as 
a negative regulator of their function, ipilimumab 
releases T cells from this inhibitory mechanism, 
enabling the uninhibited T cells to exert their full 
potential in creating antitumor immunity. Ipilimumab 
was investigated as a monotherapy in a phase 2 
trial in PDAC without success.144 Currently, it is 
being investigated in combination with gemcitabine 
in a phase 1 trial including only PDAC patients 
(NCT01473940).145 Results are not yet available. 
Nivolumab, a fully human programmed death 
1 (PD-1) ligand (PD-L1)–specific IgG4 (S228P) 
MoAb, inhibits the binding of PD-1, a T-cell coin-
hibitory receptor that is selectively expressed on 
many tumors and on cells within the tumor micro-
environment in response to inflammatory stimuli. 
Blockade of the interaction between PD-1 and 
PD-L1 by nivolumab potentiates immune responses 
in vitro and mediates preclinical antitumor activity. 
It has been evaluated in a phase 1 trial of patients 
with selected advanced cancers, including PDAC. 
Unfortunately, this drug showed activity in cancers 
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other than PDAC.146 Dual combination blockade of 
PD1 receptor by nivolumab and CTLA4 by ipilim-
umab is actually ongoing in patients with advanced 
or metastatic solid tumors, including pancreatic 
cancer (NCT01928394).147
B. enhancing Immune response
Cancer vaccines are designed to elicit an immune 
response against tumor. Several trials of vaccines, 
given alone or with other therapies, are currently 
enrolling patients with pancreatic cancer. Hyper-
Acute-Pancreas (algenpantucel-L), an allogeneic 
pancreatic cancer vaccine composed of two geneti-
cally engineered human PDAC cell lines (HAPa-1 
and HAPa-2), was evaluated in a phase 2 trial in 
addition to fluorouracil- and gemcitabine-based 
chemoradiotherapy as adjuvant treatment in PDAC 
patients. Results showed a trend toward prolonged 
disease-free survival.148 Algenpantucel is cur-
rently being investigated in a phase 3 trial (NCT 
01836432).149 
GVAX vaccine composed of two irradiated, 
granulocyte-macrophage colony-stimulating factor 
(GM-CSF)–secreting allogeneic PDA cell lines 
induces T cells against a broad array of PDAC 
antigens. CRS-207, live-attenuated Listeria mono-
cytogenes expressing mesothelin, induces innate and 
adaptive immunity.
A phase 2 trial involving GVAX vaccine and 
CRS-207 alone or combined with low-dose cyclo-
phoposphamide chemotherapy was investigated in 
previously treated metastatic PDAC patients. Active 
treatment resulted in increased survival with reduced 
toxicity.150
c.  other Signaling Pathways regulating 
the Immune response
Signaling through Notch receptors regulates the 
differentiation and function of many cell types, 
including immune cells.151 A MoAb against Notch 
2 and Notch 3 receptors, tarextumab, has been 
recently designed as an orphan drug for the treat-
ment of advanced PDAC by FDA. A randomized 
phase 1/2 trial comparing gemcitabine and nab-
paclitaxel with or without tarextumab is ongoing 
(NCT01647828).152
Ensituximab, a MoAb against human colorec-
tal and pancreatic carcinoma-associated antigens 
(CPAAs), has potential immunomodulating and 
antitumor activities. It is currently being investi-
gated in phase 1/2 clinical trials (NCT01040000, 
NCT01834235).153,154
vIII. concluSIonS
PDAC is one of most lethal cancers worldwide. 
Despite the relevance of this disease, treatment 
options have been limited and patient survival has 
not substantially changed over several decades. In the 
last few years, however, molecular understanding of 
PDAC has dramatically improved. A better knowl-
edge of the disease genetics and of the role of the 
stroma for cancer development and progression and 
as a barrier to the optimal delivery of chemotherapy 
has opened the way to new potential therapeutic 
targets for PDAC. Target discovery and novel drug 
development research is focusing on specific PDAC 
molecular hallmarks such as metabolic pathways, 
proliferative and survival signaling pathways, tumor 
microenvironment, and immunology. PDAC is driven 
by alterations of multiple genes involved in the above 
cellular pathways and processes. A small number 
of driver mutations is possibly sufficient for PDAC 
tumorigenesis. Among them, K-RAS activating muta-
tions are the most common, and targeting K-RAS 
as well as other control loops involved in the same 
pathway appears to be one of the most promising 
approaches in PDAC therapy. The combination of 
chemotherapy with novel targeted drugs as well as 
the combination of targeted agents are being explored. 
Drugs targeting stroma or the immune system are 
also offering therapeutic alternatives for PDAC. 
While cytotoxic agents are currently the reference 
drugs for the treatment of PDAC, promising data in 
the preclinical setting as well as preliminary results 
from clinical trials, underscore the importance of 
identifying druggable targets within the molecular 
hallmarks of this cancer.
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